GLP-1

Next Up in Obesity Drugs: A Timeline of What’s Coming to Market (2026–2028+)

by
New obesity drugs are expected to be approved in the US from 2026 to 2028 and beyond, offering diverse treatment options.

The fight against obesity is entering an exciting new era. With blockbuster drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) already transforming weight management, pharmaceutical giants are racing to develop next-generation therapies. The pipeline includes oral alternatives, multi-targeted injectables, and novel mechanisms that could redefine obesity treatment. Here’s a breakdown of the most anticipated drugs—and when … Read more

Sharing is Caring
Share

Myostatin’s Role in the Next Weight-Loss Revolution

by
"Fat Loss, Muscle Gain: Myostatin’s Role in the Next Weight-Loss Revolution"

Key Points Background Current weight-loss methods, including lifestyle changes, surgery, and drugs like Wegovy and Zepbound, often result in both fat and muscle loss. This can be particularly harmful for older patients, increasing fall risk and reducing strength. To solve this, pharmaceutical companies are racing to develop drugs that preserve or grow muscle while patients … Read more

Sharing is Caring
Share